Literature DB >> 21243081

How have developments in molecular imaging techniques furthered schizophrenia research?

Judy L Thompson1, Nina Urban, Anissa Abi-Dargham.   

Abstract

Molecular imaging techniques have led to significant advances in understanding the pathophysiology of schizophrenia and contributed to knowledge regarding potential mechanisms of action of the drugs used to treat this illness. The aim of this article is to provide a review of the major findings related to the application of molecular imaging techniques that have furthered schizophrenia research. This article focuses specifically on neuroreceptor imaging studies with PET and SPECT. After providing a brief overview of neuroreceptor imaging methodology, we consider relevant findings from studies of receptor availability, and dopamine synthesis and release. Results are discussed in the context of current hypotheses regarding neurochemical alterations in the illness. We then selectively review pharmacological occupancy studies and the role of neuroreceptor imaging in drug development for schizophrenia.

Entities:  

Year:  2009        PMID: 21243081      PMCID: PMC3020795          DOI: 10.2217/IIM.09.22

Source DB:  PubMed          Journal:  Imaging Med        ISSN: 1755-5191


  180 in total

1.  Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635.

Authors:  Johannes Tauscher; Shitij Kapur; N Paul L G Verhoeff; Douglas F Hussey; Zafiris J Daskalakis; Sitra Tauscher-Wisniewski; Alan A Wilson; Sylvain Houle; Siegfried Kasper; Robert B Zipursky
Journal:  Arch Gen Psychiatry       Date:  2002-06

Review 2.  The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development.

Authors:  Peter S Talbot; Marc Laruelle
Journal:  Eur Neuropsychopharmacol       Date:  2002-12       Impact factor: 4.600

3.  Dopamine and serotonin transporters in patients with schizophrenia: an imaging study with [(123)I]beta-CIT.

Authors:  M Laruelle; A Abi-Dargham; C van Dyck; R Gil; D C D'Souza; J Krystal; J Seibyl; R Baldwin; R Innis
Journal:  Biol Psychiatry       Date:  2000-03-01       Impact factor: 13.382

4.  Serotonin 5-HT2 receptors in schizophrenia: a PET study using [18F]setoperone in neuroleptic-naive patients and normal subjects.

Authors:  R Lewis; S Kapur; C Jones; J DaSilva; G M Brown; A A Wilson; S Houle; R B Zipursky
Journal:  Am J Psychiatry       Date:  1999-01       Impact factor: 18.112

5.  Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain.

Authors:  H Hall; G Sedvall; O Magnusson; J Kopp; C Halldin; L Farde
Journal:  Neuropsychopharmacology       Date:  1994-12       Impact factor: 7.853

6.  Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

Authors:  Y Okubo; T Suhara; K Suzuki; K Kobayashi; O Inoue; O Terasaki; Y Someya; T Sassa; Y Sudo; E Matsushima; M Iyo; Y Tateno; M Toru
Journal:  Nature       Date:  1997-02-13       Impact factor: 49.962

7.  Within-subject comparison of striatal D2 receptor occupancy measurements using [123I]IBZM SPECT and [11C]Raclopride PET.

Authors:  Ana M Catafau; Marina Suarez; Santiago Bullich; Jordi Llop; Gianluca Nucci; Roger N Gunn; Claire Brittain; Marc Laruelle
Journal:  Neuroimage       Date:  2009-02-20       Impact factor: 6.556

8.  Dopamine transporter density in young patients with schizophrenia assessed with [123]FP-CIT SPECT.

Authors:  J Lavalaye; D H Linszen; J Booij; P M Dingemans; L Reneman; J B Habraken; B P Gersons; E A van Royen
Journal:  Schizophr Res       Date:  2001-01-15       Impact factor: 4.939

9.  Tiagabine increases [11C]flumazenil binding in cortical brain regions in healthy control subjects.

Authors:  W Gordon Frankle; Raymond Y Cho; Rajesh Narendran; N Scott Mason; Shivangi Vora; Maralee Litschge; Julie C Price; David A Lewis; Chester A Mathis
Journal:  Neuropsychopharmacology       Date:  2008-07-09       Impact factor: 7.853

10.  Dopamine transporter change in drug-naive schizophrenia: an imaging study with 99mTc-TRODAT-1.

Authors:  Mei-Chun Hsiao; Kun-Ju Lin; Chia-Yih Liu; Kai-Yuan Tzen; Tzu-Chen Yen
Journal:  Schizophr Res       Date:  2003-12-01       Impact factor: 4.939

View more
  5 in total

1.  [Early dementia as primary syndrome of schizophrenia].

Authors:  F U Lang; R Klug; M Kunath; C Palm; I Uttner; M Jäger
Journal:  Nervenarzt       Date:  2013-05       Impact factor: 1.214

2.  Speech-induced striatal dopamine release is left lateralized and coupled to functional striatal circuits in healthy humans: a combined PET, fMRI and DTI study.

Authors:  Kristina Simonyan; Peter Herscovitch; Barry Horwitz
Journal:  Neuroimage       Date:  2012-12-28       Impact factor: 6.556

Review 3.  Reconceptualization of translocator protein as a biomarker of neuroinflammation in psychiatry.

Authors:  T Notter; J M Coughlin; A Sawa; U Meyer
Journal:  Mol Psychiatry       Date:  2017-12-05       Impact factor: 15.992

Review 4.  Dopamine regulation of human speech and bird song: a critical review.

Authors:  Kristina Simonyan; Barry Horwitz; Erich D Jarvis
Journal:  Brain Lang       Date:  2012-01-28       Impact factor: 2.381

5.  Deictic and Propositional Meaning-New Perspectives on Language in Schizophrenia.

Authors:  Vitor C Zimmerer; Stuart Watson; Douglas Turkington; I Nicol Ferrier; Wolfram Hinzen
Journal:  Front Psychiatry       Date:  2017-02-10       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.